SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
BNGO

Bionano Genomics, Inc. (NASDAQ:BNGO)

US · Delayed Price · Currency is USD
Healthcare · Medical - Instruments & Supplies
$0.82-$0.06 (-7.10%)
 
Market cap
$11.5M
Insider Score
Health Score
Analyst consensus
Listed since
Aug 21, 2018
Market Cap$11.50M-51.1%
Revenue (ttm)$31.09M+8.2%
Net Income-$30.11M+22.0%
EPS-$2.68+82.7%
Shares Out13.99M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume248,640
Open$0.90
Previous Close$0.89
Day's Range$0.82 - $0.93
52-Week Range$0.81 - $2.23
Beta1.71
AnalystsBuy
Price Target$46.50(+5555.56%)
Earnings DateMar 22, 2027

About BNGO

Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.

Address
9540 Towne Centre Drive, San Diego, CA, 92121, US
Market Cap
12 million
Employees
96
Industrial Classification
Medical - Instruments & Supplies

Bionano Genomics, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
1st Percentile Overall Score
BNGO InsiderScore:25 / 99

Bionano Genomics, Inc. scored higher than 1% of companies evaluated by InsiderBuying, and ranked 57th out of 57 stocks in the healthcare sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Bionano Genomics, Inc. bought $4.8K of stock across 1 purchase in the last 90 days, the largest of them $4.8K.

Stake Increase

The average purchase added about 100% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$9.70K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From BNGO’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-7.10%
5 Days
-17.78%
1 Month
-30.32%
6 Months
-33.69%
1 Year
-51.06%

$BNGO stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in BNGO holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by BNGO's directors and management

Net Shares Purchased by Insiders−8k−4k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

BNGO Estimated quarterly lobbying spending

Source: U.S. Senate LDA

BNGO Revenue by Segment or Geography

$3.31MTotal
Contracted services$1.80M54.52%
Rent and facilities$619.00K18.73%
Consulting$418.00K12.65%
Administrative and other$162.00K4.90%
Travel and entertainment$157.00K4.75%
Non-inventory materials$147.00K4.45%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New BNGO patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to BNGO from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in BNGO

VXFVanguard Extended Market ETF$159.60K
TYNEDirexion Nanotechnology ETF$44.83K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from BNGO’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
25.2
Analyst Ratings
32% of score
60
News & Sentiment
20% of score
72

News check: Q3 2026 earnings show record flow cell sales and positive business update, indicating strong operational momentum for Bionano Genomics.

Recent Insider Activity

Buys
2
Sells
0
Buy Value
$9.70K
Distinct Buyers
1

Insider Score Trend Over Time

-10.0 since Sep 24
0255075100Sep 24 — Insider Score 35.2Sep 25 — Insider Score 50.2Sep 26 — Insider Score 50.1Sep 27 — Insider Score 50.3Sep 28 — Insider Score 50.5Sep 29 — Insider Score 49.8Sep 30 — Insider Score 49.5Oct 1 — Insider Score 48.9Oct 2 — Insider Score 48.0Oct 3 — Insider Score 48.7Oct 4 — Insider Score 48.7Oct 5 — Insider Score 48.9Oct 6 — Insider Score 48.0Oct 7 — Insider Score 47.9Oct 8 — Insider Score 47.6Oct 9 — Insider Score 47.6Oct 10 — Insider Score 47.0Oct 11 — Insider Score 47.8Oct 12 — Insider Score 47.9Oct 13 — Insider Score 47.6Oct 14 — Insider Score 47.1Oct 15 — Insider Score 47.1Oct 16 — Insider Score 47.0Oct 17 — Insider Score 46.9Oct 18 — Insider Score 47.2Oct 19 — Insider Score 47.0Oct 20 — Insider Score 46.5Oct 21 — Insider Score 46.4Oct 22 — Insider Score 46.8Oct 23 — Insider Score 46.8Oct 24 — Insider Score 46.7Oct 25 — Insider Score 46.5Oct 26 — Insider Score 46.4Oct 27 — Insider Score 46.4Oct 28 — Insider Score 45.8Oct 29 — Insider Score 45.2Oct 30 — Insider Score 44.5Oct 31 — Insider Score 44.1Nov 1 — Insider Score 44.3Nov 2 — Insider Score 44.4Nov 3 — Insider Score 43.5Nov 4 — Insider Score 42.9Nov 5 — Insider Score 42.0Nov 6 — Insider Score 41.0Nov 7 — Insider Score 40.4Nov 8 — Insider Score 41.0Nov 9 — Insider Score 41.3Nov 10 — Insider Score 39.3Nov 11 — Insider Score 38.9Nov 12 — Insider Score 38.5Nov 13 — Insider Score 37.1Nov 14 — Insider Score 36.0Nov 15 — Insider Score 36.6Nov 16 — Insider Score 36.2Nov 17 — Insider Score 34.5Nov 18 — Insider Score 33.2Nov 19 — Insider Score 26.8Nov 20 — Insider Score 25.2Nov 21 — Insider Score 24.6Nov 22 — Insider Score 25.2Sep 24Oct 23Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

TYNEDirexion Nanotechnology ETF5.37%

Weight is the stock’s share of each fund’s holdings.